Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Research analysts at SVB Leerink issued their Q1 2021 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report issued on Monday, January 11th. SVB Leerink analyst J. Chang expects that the company will earn ($0.61) per share for the quarter. SVB Leerink currently has a “Outperform” rating and a $25.00 target price on the stock. SVB Leerink also issued estimates for Karyopharm Therapeutics’ Q4 2021 earnings at ($0.35) EPS and FY2022 earnings at ($0.97) EPS.
Several other brokerages also recently commented on KPTI. Zacks Investment Research upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, October 6th. Morgan Stanley decreased their price target on shares of Karyopharm Therapeutics from $34.00 to $32.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 3rd. Finally, BidaskClub upgraded shares of Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 5th. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $31.30.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Monday, November 2nd. The company reported ($0.73) EPS for the quarter, hitting the consensus estimate of ($0.73). The firm had revenue of $21.33 million for the quarter, compared to the consensus estimate of $21.35 million. Karyopharm Therapeutics had a negative net margin of 221.23% and a negative return on equity of 187.66%.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Karyopharm Therapeutics by 12.2% during the 3rd quarter. BlackRock Inc. now owns 7,169,789 shares of the company’s stock valued at $104,679,000 after purchasing an additional 781,127 shares during the last quarter. State Street Corp lifted its holdings in Karyopharm Therapeutics by 4.1% during the 3rd quarter. State Street Corp now owns 4,788,974 shares of the company’s stock valued at $69,919,000 after purchasing an additional 190,027 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Karyopharm Therapeutics by 9.7% during the 2nd quarter. Vanguard Group Inc. now owns 3,564,005 shares of the company’s stock valued at $67,501,000 after purchasing an additional 315,546 shares during the last quarter. Alkeon Capital Management LLC lifted its holdings in Karyopharm Therapeutics by 4.8% during the 3rd quarter. Alkeon Capital Management LLC now owns 2,164,900 shares of the company’s stock valued at $31,608,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Emerald Advisers LLC lifted its holdings in Karyopharm Therapeutics by 28.9% during the 3rd quarter. Emerald Advisers LLC now owns 1,603,253 shares of the company’s stock valued at $23,407,000 after purchasing an additional 359,042 shares during the last quarter. 93.35% of the stock is owned by hedge funds and other institutional investors.
In other news, EVP Christopher Brett Primiano sold 137,061 shares of Karyopharm Therapeutics stock in a transaction dated Tuesday, December 1st. The shares were sold at an average price of $17.53, for a total transaction of $2,402,679.33. Following the sale, the executive vice president now directly owns 82,647 shares in the company, valued at approximately $1,448,801.91. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mansoor Raza Mirza sold 5,000 shares of Karyopharm Therapeutics stock in a transaction dated Friday, December 18th. The shares were sold at an average price of $18.00, for a total transaction of $90,000.00. Following the sale, the director now owns 5,000 shares in the company, valued at $90,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 162,287 shares of company stock worth $2,817,600. 11.63% of the stock is owned by company insiders.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1.
Read More: Is a Roth IRA right for you?
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.